August 28, 2026
A Melanoma "Vaccine" Just Cleared Phase 3. The Headline Skipped the Timeline
Merck and Moderna's personalized mRNA melanoma therapy hit its Phase 3 goals. What the trial showed, how strong the evidence is, and why it's not here yet.
.svg){kind=logo}
The internet decided this summer that CPAP was finished. A once-nightly pill had cleared a big trial, the "goodbye CPAP" posts wrote themselves, and somewhere a machine you've been fighting with since 2019 felt a chill.
The pill is real and it's the first of its kind. The number going around still oversells it.
It's called AD109, taken once at bedtime. It combines two medications that work on the nerves controlling your upper airway muscles. Obstructive sleep apnea happens when those muscles go slack during sleep and your airway collapses, so you stop breathing over and over all night without knowing it. The pill keeps those muscles a little more toned so the airway stays open. It works on the cause from the inside, instead of holding the airway open with pressured air the way a CPAP machine does.
The buzz comes from a phase 3 trial called SynAIRgy, published in the American Journal of Respiratory and Critical Care Medicine in July 2026. It was a real, peer-reviewed, placebo-controlled trial in 646 adults across the US and Canada, built specifically for people who couldn't ...
Carly Malo is myStoria's Head of Concierge. She has 2 decades of experience in direct nursing care, having worked in long-term care, sports medicine, practical nursing, and fertility/reproductive health.
